1. Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational study
- Author
-
Annalisa Rizzo, L.M.E. Grimaldi, G. Vitello, Pietro Annovazzi, A. Ghezzi, Vittorio Martinelli, Marta Radaelli, Francesca Sangalli, S. Bucello, Lucia Moiola, G. Comi, Sangalli, F, Moiola, L, Bucello, S, Annovazzi, P, Rizzo, A, Radaelli, M, Vitello, G, Grimaldi, Lm, Ghezzi, A, Martinelli, V, and Comi, Giancarlo
- Subjects
Adult ,Male ,medicine.medical_specialty ,Neurology ,Efficacy ,Dermatology ,Antibodies, Monoclonal, Humanized ,Follow-Up Studie ,Cohort Studies ,Drug Hypersensitivity ,Young Adult ,Multiple Sclerosis, Relapsing-Remitting ,Natalizumab ,Internal medicine ,Product Surveillance, Postmarketing ,medicine ,Humans ,Multiple sclerosi ,Young adult ,business.industry ,Multiple sclerosis ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Psychiatry and Mental health ,Treatment Outcome ,Tolerability ,Psychiatry and Mental Health ,Female ,Observational study ,Neurology (clinical) ,Neurosurgery ,Safety ,Cohort Studie ,business ,Human ,Follow-Up Studies ,Cohort study ,medicine.drug - Abstract
To evaluate the efficacy and safety of natalizumab in patients with active relapsing-remitting multiple sclerosis (MS). We included 285 MS patients receiving natalizumab. Clinical, neuroradiological and safety data were registered every 6 months. Neutralizing antibodies (NABs) were tested after 6 months of treatment. After 1 year, the annualized relapse rate decreased to 0.26, with a significant reduction compared to the previous year (2.13). At 24 months the proportion of "relapse free" patients was 78% while that of "MRI free" patients was 69%. Considering clinical and MRI cumulative activity, "disease free" patients were 63% at 24 months. A total of 18 patients showed NABs positivity. We reported 34 cases of treatment interruptions. In conclusion, our data confirm the remarkable efficacy of natalizumab in a group of patients with higher disease activity than that of pivotal studies. © Springer-Verlag 2010.
- Published
- 2010